Yang Li Sells 1,584 Shares of Surrozen (NASDAQ:SRZN) Stock

Key Points

• VP Yang Li sold 1,584 shares on May 4 at an average price of $33.33 for a total of $52,794.72, reducing their ownership by 8.43% to 17,216 shares; the sale was disclosed in an SEC filing.
• Surrozen reported a steep quarterly loss (EPS of -$7.59 versus a -$1.29 estimate) with weak revenue of $0.53M, while the stock trades around $32.64 and the company has a market cap of about $375M.
• Analysts are mixed but the consensus is a “Moderate Buy” with a $38 price target, and institutional investors/hedge funds hold roughly 66.6% of the shares with recent position increases.

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) VP Yang Li sold 1,584 shares of Surrozen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.33, for a total transaction of $52,794.72. Following the completion of the sale, the vice president owned 17,216 shares of the company's stock, valued at $573,809.28. This represents a 8.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Surrozen Stock Performance

Shares of SRZN stock traded up $0.57 during trading hours on Tuesday, reaching $32.64. The company had a trading volume of 95,295 shares, compared to its average volume of 113,375. The business has a fifty day moving average price of $28.15 and a 200-day moving average price of $21.98. Surrozen, Inc. has a one year low of $5.90 and a one year high of $35.00. The firm has a market cap of $375.03 million, a PE ratio of -0.98 and a beta of 0.59.

Surrozen (NASDAQ:SRZN - Get Free Report) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($7.59) EPS for the quarter, missing analysts' consensus estimates of ($1.29) by ($6.30). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 7,476.67%.The company had revenue of $0.53 million during the quarter, compared to the consensus estimate of $0.66 million. Equities research analysts forecast that Surrozen, Inc. will post -4.04 EPS for the current year.

Wall Street Analysts Forecast Growth

SRZN has been the subject of a number of research analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Surrozen in a research note on Tuesday, April 21st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $40.00 price target on shares of Surrozen in a research note on Tuesday, March 24th. HC Wainwright reiterated a "buy" rating and issued a $36.00 price target (up from $32.00) on shares of Surrozen in a research note on Tuesday, March 24th. TD Cowen initiated coverage on shares of Surrozen in a research note on Tuesday, April 21st. They issued a "buy" rating for the company. Finally, Wall Street Zen upgraded shares of Surrozen from a "sell" rating to a "hold" rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.00.

Hedge Funds Weigh In On Surrozen

A number of institutional investors and hedge funds have recently made changes to their positions in SRZN. Geode Capital Management LLC boosted its holdings in shares of Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock worth $277,000 after buying an additional 5,702 shares during the last quarter. Armistice Capital LLC purchased a new position in shares of Surrozen in the second quarter worth approximately $536,000. Vanguard Group Inc. boosted its holdings in shares of Surrozen by 21.7% in the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company's stock worth $3,433,000 after buying an additional 47,468 shares during the last quarter. Acuta Capital Partners LLC boosted its holdings in shares of Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company's stock worth $2,299,000 after buying an additional 8,415 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Surrozen in the third quarter worth approximately $889,000. Hedge funds and other institutional investors own 66.57% of the company's stock.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.